StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell

Posted by Linda Flegge on Nov 13th, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock traded down $0.04 on Tuesday, reaching $1.18. 118,456 shares of the company were exchanged, compared to its average volume of 57,275. The company has a market cap of $6.28 million, a price-to-earnings ratio of -0.34 and a beta of 0.40. Brainstorm Cell Therapeutics has a 1 year low of $1.09 and a 1 year high of $11.89. The business has a 50-day moving average price of $2.77 and a 200 day moving average price of $4.85.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). During the same period last year, the company earned ($4.05) earnings per share. As a group, equities analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.